On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
ACADEMIA
4 Scientific Societies Submit Proposal to Health Minister to Ensure Stable Antibiotic Supplies
Four scientific societies have submitted a proposal for the stable supply of antibiotics to the health minister, calling on the government to keep tabs on the production systems for such drugs and to evaluate the risks of sudden supply stoppages.…
To read the full story
Related Article
- Japan Sketches Out Stable API Supply Measures, Set to Pick Key Drugs from 551 Candidates by March-End
August 4, 2020
- 418 Key Drug Candidates Listed by 36 Societies, Panel to Outline Stable Supply Measures at Next Meeting
June 29, 2020
- Stable Supply Debate Set to Heat Up in Japan, Scientific Societies to Select Key Drugs by June-End
June 9, 2020
- New Stable Supply Panel Wants to Define “Key Drugs” by This Summer
March 30, 2020
- 3 Key Antibiotics to Receive Price Raises through Unprofitability Re-Pricing
March 18, 2020
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
ACADEMIA
- Infectious Diseases Society Proposes Testing for Both COVID-19, Flu as It Girds for Simultaneous Outbreaks
August 7, 2020
- NCC, BrightPath Identify Peptide Vaccine Candidates for COVID-19
July 31, 2020
- Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.
July 13, 2020
- Univ. of Tokyo, Biogen Expand Neurological Research Program for 2 Years
July 9, 2020
- Kyoto University, NIBIOHN to Join Forces on Drug Discovery
July 8, 2020
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…